Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients (Q33488688)

27 July 2017

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients (English)

1 reference

27 July 2017

0 references

1 reference

D J Winston

1

1 reference

27 July 2017

D Wirin

series ordinal

2

1 reference

27 July 2017

A Shaked

series ordinal

3

1 reference

27 July 2017

R W Busuttil

series ordinal

4

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 July 1995

1 reference

27 July 2017

1 reference

27 July 2017

346

1 reference

27 July 2017

69-74

1 reference

27 July 2017

8967

1 reference

Cytomegalovirus infection after liver transplantation: clinical manifestations and strategies for prevention

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Clinical patterns of cytomegalovirus disease after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

One thousand liver transplants. The lessons learned

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Evaluation of oral acyclovir therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Prevalence of Resistance in Patients Receiving Ganciclovir for Serious Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

The cost impact of cytomegalovirus disease in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Increased Pulmonary Superinfections in Cardiac-Transplant Patients Undergoing Primary Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

The prevention of cytomegalovirus disease in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Antigenemia in the Diagnosis and Monitoring of Active Cytomegalovirus Infection after Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Relationship of the polymerase chain reaction for cytomegalovirus to the development of hepatitis in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992110-9

7 January 2021

10.1016/S0140-6736(95)92110-9

Identifiers

DOI

1 reference

27 July 2017

1 reference